
Asahi Kasei Pharma advances refractory disease drug to trial
Asahi Kasei Pharma has advanced its treatment for refractory diseases to Phase I clinical trial. AK1960, a novel Endothelin A (ETA) receptor antagonist, has been developed in collaboration with drug discovery company Alchemedicine, which entered a license agreement with Asahi Kasei Pharma in 2022. In preclinical… Read More







